The North America Pain Patch Market should witness market growth of 3.7% CAGR during the forecast period (2023-2029).
Due to consumers' increasing preference for online buying over conventional ways of purchasing, e-commerce has emerged as a crucial tool for small and large enterprises globally. The pain patch has expanded as a result of various animations distributed through health applications that instruct users on how to control their pain and use cutting-edge drug delivery systems. Effective pain treatment is in high demand, not just in wealthy nations; this demand is also seen in developing nations, which helps the market expand.
It is anticipated that during the forecast period, manufacturers will ramp up their promotional efforts and that the general public will become more aware of the need for appropriate pain management products. The rise in acceptance of novel drug delivery systems for pain management with fewer side effects, the rise in diagnoses of chronic pain disorders, and the rise in cases of arthritis, cancer, and neuropathic pain are additional factors that are expected to contribute to the growth of the pain patch market during the forecast period. In addition, the market is also growing as a result of proper post-operative pain conditions counseling and approvals for innovative pain patches.
Estimates of chronic pain among U.S. adults based on the population range from 11% to 40%, with significant subgroup heterogeneity. In order to accurately determine the prevalence of chronic pain and high-impact chronic pain (i.e., chronic pain that frequently restricts life or work activities), the 2016 National Pain Strategy called for more accurate prevalence estimates. This would help in introducing & implementing population-wide pain interventions. The CDC examined the 2016 National Health Interview Survey (NHIS) data to estimate the prevalence of chronic pain and high-impact chronic pain in the United States. These factors are increasing market growth.
The US market dominated the North America Pain Patch Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $1,610.9 million by 2029. The Canada market is estimated to grow at a CAGR of 6.1% during (2023-2029). Additionally, The Mexico market should witness a CAGR of 5.1% during (2023-2029).
Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Type, the market is segmented into Prescription Medicines and OTC Medicines. Based on Product Type, the market is segmented into Non-Opioid Patches and Opioid Patches. Based on Non-Opioid Patches Type, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs, Methyl Salicylate, Lidocaine and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include NEXGEL, Inc. Viatris, Inc. Johnson & Johnson. Teva Pharmaceutical Industries Ltd. Grunenthal GmbH. Sorrento Therapeutics, Inc. Hisamitsu Pharmaceutical Co. Inc. Endo International PLC. Purdue Pharma L.P. Amneal Pharmaceuticals, Inc.
Due to consumers' increasing preference for online buying over conventional ways of purchasing, e-commerce has emerged as a crucial tool for small and large enterprises globally. The pain patch has expanded as a result of various animations distributed through health applications that instruct users on how to control their pain and use cutting-edge drug delivery systems. Effective pain treatment is in high demand, not just in wealthy nations; this demand is also seen in developing nations, which helps the market expand.
It is anticipated that during the forecast period, manufacturers will ramp up their promotional efforts and that the general public will become more aware of the need for appropriate pain management products. The rise in acceptance of novel drug delivery systems for pain management with fewer side effects, the rise in diagnoses of chronic pain disorders, and the rise in cases of arthritis, cancer, and neuropathic pain are additional factors that are expected to contribute to the growth of the pain patch market during the forecast period. In addition, the market is also growing as a result of proper post-operative pain conditions counseling and approvals for innovative pain patches.
Estimates of chronic pain among U.S. adults based on the population range from 11% to 40%, with significant subgroup heterogeneity. In order to accurately determine the prevalence of chronic pain and high-impact chronic pain (i.e., chronic pain that frequently restricts life or work activities), the 2016 National Pain Strategy called for more accurate prevalence estimates. This would help in introducing & implementing population-wide pain interventions. The CDC examined the 2016 National Health Interview Survey (NHIS) data to estimate the prevalence of chronic pain and high-impact chronic pain in the United States. These factors are increasing market growth.
The US market dominated the North America Pain Patch Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $1,610.9 million by 2029. The Canada market is estimated to grow at a CAGR of 6.1% during (2023-2029). Additionally, The Mexico market should witness a CAGR of 5.1% during (2023-2029).
Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Type, the market is segmented into Prescription Medicines and OTC Medicines. Based on Product Type, the market is segmented into Non-Opioid Patches and Opioid Patches. Based on Non-Opioid Patches Type, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs, Methyl Salicylate, Lidocaine and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include NEXGEL, Inc. Viatris, Inc. Johnson & Johnson. Teva Pharmaceutical Industries Ltd. Grunenthal GmbH. Sorrento Therapeutics, Inc. Hisamitsu Pharmaceutical Co. Inc. Endo International PLC. Purdue Pharma L.P. Amneal Pharmaceuticals, Inc.
Scope of the Study
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Type
- Prescription Medicines
- OTC Medicines
By Product Type
- Non-Opioid Patches
- Nonsteroidal Anti-Inflammatory Drugs
- Methyl Salicylate
- Lidocaine
- Others
- Opioid Patches
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- NEXGEL, Inc.
- Viatris, Inc.
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Grunenthal GmbH
- Sorrento Therapeutics, Inc.
- Hisamitsu Pharmaceutical Co. Inc.
- Endo International PLC
- Purdue Pharma L.P.
- Amneal Pharmaceuticals, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Pain Patch Market, by Distribution Channel
1.4.2 North America Pain Patch Market, by Type
1.4.3 North America Pain Patch Market, by Product Type
1.4.4 North America Pain Patch Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Pain Patch Market by Distribution Channel
3.1 North America Drug Stores & Retail Pharmacies Market by Country
3.2 North America Hospital Pharmacies Market by Country
3.3 North America Online Providers Market by Country
Chapter 4. North America Pain Patch Market by Type
4.1 North America Prescription Medicines Market by Country
4.2 North America OTC Medicines Market by Country
Chapter 5. North America Pain Patch Market by Product Type
5.1 North America Non-Opioid Patches Market by Country
5.2 North America Pain Patch Market by Non-Opioid Patches Type
5.2.1 North America Nonsteroidal Anti-Inflammatory Drugs Market by Country
5.2.2 North America Methyl Salicylate Market by Country
5.2.3 North America Lidocaine Market by Country
5.2.4 North America Others Market by Country
5.3 North America Opioid Patches Market by Country
Chapter 6. North America Pain Patch Market by Country
6.1 US Pain Patch Market
6.1.1 US Pain Patch Market by Distribution Channel
6.1.2 US Pain Patch Market by Type
6.1.3 US Pain Patch Market by Product Type
6.1.3.1 US Pain Patch Market by Non-Opioid Patches Type
6.2 Canada Pain Patch Market
6.2.1 Canada Pain Patch Market by Distribution Channel
6.2.2 Canada Pain Patch Market by Type
6.2.3 Canada Pain Patch Market by Product Type
6.2.3.1 Canada Pain Patch Market by Non-Opioid Patches Type
6.3 Mexico Pain Patch Market
6.3.1 Mexico Pain Patch Market by Distribution Channel
6.3.2 Mexico Pain Patch Market by Type
6.3.3 Mexico Pain Patch Market by Product Type
6.3.3.1 Mexico Pain Patch Market by Non-Opioid Patches Type
6.4 Rest of North America Pain Patch Market
6.4.1 Rest of North America Pain Patch Market by Distribution Channel
6.4.2 Rest of North America Pain Patch Market by Type
6.4.3 Rest of North America Pain Patch Market by Product Type
6.4.3.1 Rest of North America Pain Patch Market by Non-Opioid Patches Type
Chapter 7. Company Profiles
7.1 NEXGEL, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Research & Development Expenses
7.2 Viatris, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental Analysis
7.2.4 Research & Development Expense
7.3 Johnson & Johnson
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental &Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 SWOT Analysis
7.4 Teva Pharmaceutical Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Grünenthal GmbH
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expenses
7.5.5 Recent strategies and developments:
7.5.5.1 Approvals & Trials:
7.6 Sorrento Therapeutics, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental Analysis
7.6.4 Research & Development Expenses
7.7 Hisamitsu Pharmaceutical Co. Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Recent strategies and developments:
7.7.3.1 Product Launches and Product Expansions:
7.8 Endo International PLC
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental Analysis
7.8.4 Research & Development Expense
7.9 Purdue Pharma L.P.
7.9.1 Company Overview
7.10. Amneal Pharmaceuticals, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental Analysis
7.10.4 Research & Development Expenses
7.10.5 Recent strategies and developments:
7.10.5.1 Partnerships, Collaborations, and Agreements:
7.10.5.1 Approvals & Trials:
Companies Mentioned
- NEXGEL, Inc.
- Viatris, Inc.
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Grunenthal GmbH
- Sorrento Therapeutics, Inc.
- Hisamitsu Pharmaceutical Co. Inc.
- Endo International PLC
- Purdue Pharma L.P.
- Amneal Pharmaceuticals, Inc.
Methodology
LOADING...
